Multivariate analyses of prognostic factors in acute myeloid leukemia: Relevance of cytogenetic abnormalities and CD34 expression

Neoplasma

Volumn 52, Issue 5, 2005, Pages 402-410

  Junghanss, C ^a   Waak, M ^a   Knopp, A ^a   Kleine, H D ^a   Kundt, G ^a   Leithauser M ^a   Hilgendorf, I ^a   Wolff, D ^a   Casper, J ^a   Freund, M ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

AML; CD34 antigen; Cytogenetic Abnormalities; Hematopoietic stem cell transplantation; Leukemia; Prognosis

Indexed keywords

ANTHRACYCLINE; CD34 ANTIGEN; CYTARABINE; IDARUBICIN; LACTATE DEHYDROGENASE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PALLIATIVE THERAPY; CHROMOSOME ABERRATION; FEMALE; GERMANY; HUMAN; KARYOTYPE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 26044481960     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. BAER MR, STEWART CC, LAWRENCE D, ARTHUR DC, BYRD JC et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with T(8;21)(Q22;Q22). Blood 1997; 90(4): 1643-1648.
2. BENE MC, CASTOLDIG, KNAPP W, LUDWIG WD, MATUTES E et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9(10): 1783-1786.
3. BENNETT JM, CATOVSKY D, DANIEL MT, FLANDRIN G, GALTON DA et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-Operative Group. Br J Haematol 1976; 33(4): 451-458.
4. BRADSTOCK K, MATTHEWS J, BENSON E, PAGE F, BISHOP J. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 1994; 84(4): 1220-1225.
5. BRINCKER H, CHRISTENSEN BE, SCHMIDT KG, HORNSTRUP MK. Itraconazole treatment of pulmonary aspergillosis in leukaemia patients during a nosocomial epidemic associated with indoor building renovation. Mycoses 1991; 34(9-10): 395-400.
6. BÜCHNER T, HIDDEMANN W, BERDEL WE, WÖRMANN, B, SCHOCH C et al. 6-Thioguanine, Cytarabine, and Daunorubicin (TAD) and high-dose Cytarabine and Mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by Sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a Randomized Trial of the German AML Cooperative Group. J Clin Oncol 2003; 21(24): 4496-4504.
7. BÜCHNER T, HIDDEMANN W, WÖRMANN B, LÖFFLER H, GASSMANN W et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose Cytarabine with Mitoxantrone instead of standard-dose Cytarabine with Daunorubicin and 6-Thioguanine: a Randomized Trial by the German AML Cooperative Group 1999; 93(12): 4116-4124.
8. BULLINGER L, DÖHNER K, BAIR E, FRÖHLING S, SCHLENK RF et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350(16): 1605-1616.
9. BURNETT AK, WHEATLEY K, GOLDSTONE AH, STEVENS RF, HANN IM et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 Trial. Br J Haematol 2002; 118(2): 385-400.
10. BYRD JC, MROZEK K, DODGE RK, CARROLL AJ, EDWARDS CG et al. Pretreatment Cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results From Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100(13): 4325-4336.
11. CASASNOVAS RO, SLIMANE FK, GARAND R, FAURE GC, CAMPOS L et al. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome. Leukemia 2003; 17(3): 515-527.
12. CREUTZIG U, HARBOTT J, SPERLING C, RITTER J, ZIMMERMANN M et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 1995; 86(8): 3097-3108.
13. DALAL BI, WU V, BARNETT MJ, HORSMAN DE, SPINELLI JJ et al. Induction failure in de novo acute myelogenous leukemia is associated with expression of high levels of CD34 antigen by the leukemic blasts. Leuk Lymphoma 1997; 26(3-4): 299-306.
14. FERRANT A, LABOPIN M, FRASSONI F, PRENTICE HG, CAHN JY et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation Study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997; 90(8): 2931-2938.
15. FROHLING S, SCHLENK RF, STOLZE I, BIHLMAYR J, BENNER A et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004; 22(4): 624-633.
16. GRIMWADE D, WALKER H, HARRISON G, OLIVER F, CHATTERS S et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (aml): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 Trial. Blood 2001; 98(5): 1312-1320.
17. GRIMWADE D, WALKER H, OLIVER F, WHEATLEY K, HARRISON C et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 Trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92(7): 2322-2333.
18. HAFERLACH T, KERN W, SCHOCH C, SCHNITTGER S, SAUERLAND MC et al. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in Trials of the German AML Cooperative Group. Haematologica 2004; 89(4): 408-418.
19. HAFERLACH T, SCHOCH C, LÖFFLER H, GASSMANN W, KERN W et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group Studies. J Clin Oncol 2003; 21(2): 256-265.
20. HELBIG W, KRAHL R, KUBEL M, SCHWENKE H, HEROLD M et al. East-German Study Group: Long-term results in adult AML: comparison of postremission chemotherapy (CT) vs. autologous BMT vs. allogeneic B MT. In: Hiddemann W et al. Acute Leukemia V. Berlin Heidelberg New York: Springer-Verlag 1996: 373-379.
21. KAPLAN EL, MEIER P. Nonparametric-estimation from incomplete observations. J Am Statistic Assoc 1958; 53(282): 457-481.
22. KERN W, SCHOCH C, HAFERLACH T, BRAESS J, UNTERHALT M et al. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose Cytosine Arabinoside and Mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 2000; 14(2): 226-231.
23. LANZA F, RIGOLIN GM, MORETTIS, LATORRACA A, CASTOLDI G. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia. Leuk Lymphoma 1994; 13 Suppl 1: 81-85.
24. LEGRANDO, PERROT JY, BAUDARD M, CORDIER A, LAUTIER R et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000; 96(3): 870-877.
25. LÖWENBERG B, SUCIU S, ARCHIMBAUD E, HAAK H, STRYCKMANS P et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16(3): 872-881.
26. MAURITZSON N, ALBIN M, RYLANDER L, BILLSTROM R, AHLGREN T et al. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001. Leukemia 2002; 16(12): 2366-2378.
27. MITELMAN F. ISCN 1995, Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature. Basel, Karger 1995.
28. OREN I, HADDAD N, FINKELSTEIN R, ROWE JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001; 66(4): 257-262.
29. PETO R, PIKE MC, ARMITAGE P, BRESLOW NE, COX DR et al. Design and analysis of randomized clinical-trials requiring prolonged observation of each patient. 2. Analysis and examples. Brit J Cancer 1997; 35(1): 1-39.
30. PULSONI A, PAGANO L, LATAGLIATA R, CASINI M, CERRI R et al. Survival of elderly patients with acute myeloid leukemia. Haematologica 2004; 89(3): 296-302.
31. REPP R, SCHAEKEL U, HELM G, THIEDE C, SOUCEK S et al. Immunophenotyping is an independent factor for risk stratification in AML. Cytometry 2003; 53B(1): 11-19.
32. ROMBOUTS WJ, BLOKLAND I, LÖWENBERG B, PLOEMACHER RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the FltS gene. Leukemia 2000; 14(4): 675-683.
33. SCHNITTGER S, SCHOCH C, DUGAS M, KERN W, STAIB P et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100(1): 59-66.
34. SCHOCH C, HAFERLACH T, HAASE D, FONATSCH C, LÖFFLER H et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001; 112(1): 118-126.
35. SCHOCH C, KERN W, SCHNITTGER S, HIDDEMANN W, HAFERLACH T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with T-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18(1): 120-125.
36. SCHOCH C, SCHNITTGER S, BURSCH S, GERSTNER D, HOCHHAUS A et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16(1): 53-59.
37. SLOVAK ML, KOPECKY KJ, CASSILETH PA, HARRINGTON DH, THEIL KS et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96(13): 4075-4083.
38. SPERLING C, BÜCHNER T, CREUTZIG U, RITTER J, HARBOTT J et al. Clinical, morphologic, cytogenetic and prognostic implications of Cd34 expression in childhood and adult de-novo AML. Leukemia & Lymphoma 1995; 17(5-6): 417-426.
39. STEIN AS, O'DONNELL MR, SLOVAK ML, NADEMANEE A, DAGIS A et al. High-dose cytosine arabinoside and daunorubicin rubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission. Leukemia 2000; 14(7): 1191-1196.
40. STIREWALT DL, KOPECKY KJ, MESHINCHI S, APPELBAUM FR, SLOVAK ML et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97(11): 3589-3595.
41. SUCIU S, MANDELLI F, DE WITTE T, ZITTOUN R, GALLO E et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EO RTC/GIME-MAAML-10 Trial. Blood 2003; 102(4): 1232-1240.
42. THIEDE C, STEUDEL C, MOHR B, SCHAICH M, SCHAKEL U, PLATZBECKER U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99(12): 4326-4335.
43. UHAREK L, KRAHL R, POENISCH W, BECKER C, MANTOVANI L et al. Treatment of acute myeloid leukemia (AML) in patients under and over the age of 60: report of the AML 96-#033 and AML 97-#038 study of the East German Hematology and Oncology Study Group (OSHO). Onkologie 2001; 24 Suppl. 6: 40. (Abstract)
44. VALK PJ, VERHAAK RG, BEIJEN MA, ERPELINCK CA et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350(16): 1617-1628.
45. VARDIMAN JW, HARRIS NL, BRUNNING RD. The World Health Organization (WHO) Classification of the Myeloid Neoplasms. Blood 2002; 100(7): 2292-2302.
46. WEEMS JJ JR, DAVIS BJ, TABLAN OC, KAUFMAN L, MARTONE WJ. Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy. Infect Control 1987; 8(2): 71-75.
47. WEIDEN PL, FLOURNOY N, THOMAS ED, PRENTICE R, FEFER A et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300(19): 1068-1073.
48. WHEATLEY K, BURNETT AK, GOLDSTONE AH, GRAY RG, HANNIM et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 Trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999; 107(1): 69-79.